You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double.
Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased.
The health IT and precision oncology arm of Patrick Soon-Shiong's NantWorks conglomerate narrowed its quarterly net loss by 32 percent during the quarter.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.
The company turned its first-ever quarterly profit after a series of asset sales and cutbacks in money-losing molecular tests.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.
Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.
News items for the in vitro diagnostics industry for the week of March 16, 2020.